Efficacy and Safety of Pembrolizumab or Pembrolizumab plus Chemotherapy vs Chemotherapy Alone for Patients with First-line, Advanced Gastric Cancer: The KEYNOTE-062 Phase 3 Randomized Clinical Trial

Kohei Shitara, Eric Van Cutsem, Yung Jue Bang, Charles Fuchs, Lucjan Wyrwicz, Keun Wook Lee, Iveta Kudaba, Marcelo Garrido, Hyun Cheol Chung, Jeeyun Lee, Hugo Raul Castro, Wasat Mansoor, Maria Ignez Braghiroli, Nina Karaseva, Christian Caglevic, Luis Villanueva, Eray Goekkurt, Hironaga Satake, Peter Enzinger, Maria AlsinaAl Benson, Joseph Chao, Andrew H. Ko, Zev A. Wainberg, Uma Kher, Sukrut Shah, S. Peter Kang, Josep Tabernero

Research output: Contribution to journal › Article › peer-review

421 Citations (Scopus)

Fingerprint

Dive into the research topics of 'Efficacy and Safety of Pembrolizumab or Pembrolizumab plus Chemotherapy vs Chemotherapy Alone for Patients with First-line, Advanced Gastric Cancer: The KEYNOTE-062 Phase 3 Randomized Clinical Trial'. Together they form a unique fingerprint.

Pharmacology, Toxicology and Pharmaceutical Science